InvestingPro’s Fair Value spotted 65% gain in Inspire Medical stock

Inspire Medical Systems shares rose 65.38% from $41.19 in early June to roughly $73 by early September 2026, exceeding InvestingPro's initial $62.22 fair-value estimate; its updated intrinsic-value estimate is $79.40. The company beat Q2 2026 earnings expectations, with EBITDA increasing to $71.3 million and EPS to $4.66, prompting price-target increases from Stifel, Piper Sandler and RBC and an Oppenheimer upgrade. The successful Inspire V launch and 84.47% gross margin reinforce the bullish outlook for its sleep-apnea therapy business.

Analysis

The relevant signal is no longer the original valuation dislocation: after a sharp rerating, the remaining published upside is too narrow to justify chasing INSP absent a material upward revision to procedure-volume growth or long-term margin targets. The article is promotional and contains a mismatched headline, while its quoted earnings and profitability figures require reconciliation against filed financials; treat the “fair value” estimate as marketing rather than an independently actionable price target. Near term, upgrades can support momentum, but a premium multiple leaves the shares exposed to even modest deceleration in implant growth, sales-force productivity, or guidance conservatism at the next earnings print.

The more important 6-18 month question is whether hypoglossal nerve stimulation remains a high-growth, capacity-constrained therapy or becomes a more competitive category. INSP’s economics depend on ENT/surgeon training, sleep-center referrals, prior-authorization approval rates, and CMS/commercial reimbursement—not solely product demand. RMD is the incumbent alternative for less-invasive sleep-apnea treatment, while NYXH and LIVN represent potential competitive entrants in implantable neurostimulation; successful clinical, regulatory, or reimbursement progress from either could compress INSP’s terminal-value assumptions before it visibly affects revenue.

Key Decisions for Investors

• Do not add to INSP solely on the cited valuation framework after the rerating. Reassess only after the next earnings release confirms procedure growth and raises forward revenue/EBITDA guidance; a post-results upside gap greater than 15% to independently derived valuation would be a more attractive entry condition.
• For existing INSP longs, retain a reduced core position through the next earnings catalyst but protect gains with a 3-6 month collar or trim into further analyst-target-driven strength. Thesis is falsified by a material cut to implant-volume guidance, deterioration in gross margin, or evidence that authorization/implant conversion is slowing.
• Build a competitive watchlist rather than force a pair trade: monitor NYXH regulatory and commercialization milestones and LIVN sleep-apnea trial updates over the next 6-12 months. A credible reimbursement pathway for a competing implantable therapy would be a negative multiple catalyst for INSP even before meaningful sales emerge.
• Use RMD as the lower-volatility sleep-apnea exposure if seeking category participation; its diversified consumables base reduces single-product reimbursement and procedural-capacity risk relative to INSP. The trade-off is lower direct upside to HGNS adoption.